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Abstract
Purpose of Review Pathological complete response is seen in approximately one fifth of rectal cancer patients following neoad-
juvant chemoradiation. Since these patients have excellent oncological outcomes, there has been a rapidly growing interest in
organ preservation for those who develop a clinical complete response. We review the watch-and-wait strategy and focus on all
aspects of this hot topic, including who should be considered for this approach, how should we identify treatment response and
what are the expected outcomes.
Recent Findings The major challenges in interpreting the data on watch-and-wait are the significant heterogeneity of patients
selected for this approach and of methods employed to identify them. The evidence available comes mostly from retrospective
cohort studies, but has shown good oncological outcomes, including the rate of successful salvage surgery, locoregional control
and overall survival.
Summary There is currently not enough and not robust enough evidence to support watch-and-wait as a standard approach,
outside a clinical trial, for patients achieving clinical complete response following neoadjuvant chemoradiation. Furthermore,
there is a lack of data on long-term outcomes. However, the results we have so far are promising, and there is therefore an urgent
need for randomised control studies such as the TRIGGER trial to confirm the safety of this strategy.
Keywords Watch and wait . Deferral of surgery . Non-operative management . Complete response . Rectal cancer . Organ
preservation
Introduction
The standard treatment for high-risk non-metastatic rectal ad-
enocarcinoma is neoadjuvant chemoradiation (nCRT) follow-
ed by total mesorectal excision (TME) with or without adju-
vant chemotherapy. This strategy provides good oncological
outcomes, with a rate of local relapse of less than 10% [1, 2].
However, TME is a radical surgical procedure with a signifi-
cant risk of perioperative morbidities, including bowel, sexual
and urinary dysfunction [3–7]. Moreover, in advanced low
rectal cancers, the outcome of treatment frequently results in
permanent stoma formation.
We have known for a long time now that radiotherapy can
cure cancer. Nigro and his team paved the way in the early
1970s, believing in the role of definitive chemoradiation in
squamous cell carcinoma of the anal canal [8]. It took several
years to build enough evidence to support a radical change of
practice, but it is now the standard management and surgery is
considered a salvage procedure. In rectal cancer, it is not rea-
sonable to hope for the same outcome, the main reason being
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the difference in sensitivity to chemoradiation between ade-
nocarcinoma and squamous cell carcinoma. Nevertheless,
pathological complete response (pCR) is seen in 10–25% of
rectal cancers following nCRT [9]. Angelita Habr-Gama, like
Norman Nigro, has pioneered a similar approach and has
defended for more than a decade a non-operative management
in rectal cancer patients who achieved a good response to
chemoradiation [10]. The oncological community was scepti-
cal at first, but now interest is growing fast. The watch-and-
wait (W&W) approach is attractive, both to patients and cli-
nicians. It has shown excellent outcomes, as long as candi-
dates are carefully selected and appropriately monitored.
Below is a review of this management strategy, focusing on
the latest advances and future directions.
Overview and Background
In 2004, Habr-Gama and her team, from São Paulo in Brazil,
published their first long-term outcomes of a cohort of patients
managed with a non-operative strategy after having achieved
a clinical complete response (cCR) following nCRT [10]. Two
hundred and sixty-five patients with resectable distal rectal
cancer received standard nCRT. Patients were reassessed at
8 weeks following treatment, using clinical, radiological and
endoscopic examinations. Those with a cCR avoided imme-
diate surgery and entered a strict surveillance program.
Seventy-one patients (26.8%) obtained cCR and formed this
observation group. With a median follow-up of 57.3 months,
only two patients had local tumour regrowth, and three pa-
tients developed a systemic recurrence. The 5-year overall
survival and disease-free survival rates were 100 and 92%,
respectively. This landmark study revealed an entire new con-
cept in rectal cancer management and indicated the potential
for organ preservation. Since then, the results have been up-
dated, the treatment schedule has changed and many cancer
centres are now sharing their own results and helping to build
the evidence. Despite this, still many aspects of the W&W
approach are undefined or controversial.
Patient Selection for Preoperative Therapy
The main challenge with W&W is the selection of patients
who can be considered for this approach. The evidence avail-
able comes mainly from retrospective data, with great varia-
tions on who has been offered surveillance, including patients
characteristics and tumour stage. Furthermore, some studies
have used inaccurate and insufficient staging modalities, and
others have not even reported on tumour staging at baseline.
This heterogeneity limits the interpretation of data.
Patients Not Fit for Radical Resection
There are patients whose comorbidities or performance status
preclude any attempt at radical operation, who are instead
offered CRT or short-course radiotherapy as an alternative
for definitive treatment. Some of them appear to achieve a
cCR and are being subsequently monitored, even though sal-
vage radical surgery will never be an option in case of tumour
regrowth. These patients form an entirely different entity and
should be excluded from trials involving W&W. The essence
of active surveillance is in patients who are able to avoid
surgery, but to whom the procedure will be considered at a
time when we feel we need to intervene.
Patients Who Wish to Avoid Abdominoperineal
Excision (APE) at Any Cost
A large number of patients end up being monitored because
they decline radical surgery. Most of the time, they receive
long-course CRT with or without local excision, and those
who achieve a cCR or nearCR enter a surveillance program.
These patients represent a significant proportion of patients in
the retrospective studies on W&W. Unfortunately, their base-
line characteristics are often poorly recorded, making it diffi-
cult to know if they would have normally been offered nCRT
on a basis of high-risk tumour at baseline. At present, it is not
possible to advise a patient who is facing an APE what the
likelihood is that preoperative CRTwill succeed in achieving a
CR and thus the likely success of a W&Wapproach. Since the
pCR rates have been reported to be approximately 25% at
best, it is therefore logical to conclude that additional RT
where it is not indicated in the hope of achieving CR may
not succeed in up to 75% of patients.
Patients with Early-Stage Low Tumours
Patients with early-stage low rectal tumours, without any
adverse features, amenable to local excision or transanal
endoscopic microsurgery should undergo the procedure
without neoadjuvant treatment. If histopathology confirms
the full excision and initial low risk preoperative staging,
there is no indication for further treatment, and this ap-
proach provides excellent oncological and functional out-
comes. However, when high risk features are present, such
as third submucosal layer (sm3) invasion, positive margin,
grade 3, lymphovascular invasion, tumour budding or mu-
cinous subtype, and in cases of pT2 tumours, local resec-
tion alone is not sufficient. Local and/or regional recur-
rences can be seen in as much as 20% of cases [11]. The
standard treatment for completion is radical resection, and
since the tumours are low, in the majority of cases it results
in a permanent stoma. In the context of organ preservation,
only few studies have included patients with early-stage
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tumours. Habr-Gama et al. did a retrospective study
assessing the outcomes of a W&W strategy on patients
with cT2N0 rectal adenocarcinoma, less than 7 cm from
the anal verge, following two different regimen of nCRT
[12•]. Patients in the ‘extended’ CRT group (54Gy of radi-
ation and 6 cycles of 5-fluorouracil (5FU)-based chemo-
therapy) were more likely to achieve a cCR compared to
the standard group (50.4 Gy and 2 cycles of 5FU-based
chemotherapy) (85.7 vs 56.6%, p < 0.001). As mentioned
above, in the initial study by Habr-Gama [10], the rate of
cCR was 26.8% for the entire cohort, which comprised T3
tumours in 69% of cases. Therefore, achieving a rate of
cCR of 85%, or even 56% with a standard regimen of
nCRT, is impressive and suggests the potential of early
tumours for W&W. Similarly, an Italian group of investi-
gators have cumulated several years of experience in organ
preservation in early-stage low rectal cancers. They have
reported in 2012 the results of a prospective randomised
clinical trial comparing endoluminal locoregional resection
(ELRR) with laparoscopic total mesorectal excision (TME)
for early-stage cancers following nCRT [13]. Eligible pa-
tients had clinically staged T2N0M0 disease (staging mo-
dalities including endorectal ultrasonography, sigmoidos-
copy with biopsies, pelvic MRI and whole-body CT), lo-
cated within 6 cm of the anal verge, grade 1 or 2 tumours
with a diameter of less than 3 cm. Patients with
lymphovascular or perineural invasion were excluded.
The patients in the study received upfront nCRT (50.4 Gy
in 5 weeks with concomitant 5FU), had restaging investi-
gations 6 weeks after treatment and were then randomised
between ELRR and TME. With a median follow-up of
9.6 years, there was no statistically significant difference
between the two groups with regards to locoregional recur-
rences, rate of distant metastases, cancer-specific survival,
disease-free survival and overall survival. The rate of pCR
with nCRT was approximately 27% (28% in ELRR group,
26% in TME group). Other studies investigated local exci-
sion following nCRT in early-stage low rectal cancer and
reported higher rates of pCR (49–59%) [14•, 15, 16]. All
these studies provide interesting data in favour of nCRT
followed by surveillance or local resection in patients with
early-stage low cancers, suggesting that these patients
might actually be ideal candidates for organ preservation.
However, they involve a relatively small number of pa-
tients. The STAR-TREC trial (NCT02945566) is ongoing
and should help clarify the question. Although promising,
this subject raises an ethical issue. Unless there is a threat-
ened surgical resection margin, which is considered as a
high risk feature, patients with early-stage rectal cancer are
not typically considered for neoadjuvant treatment.
Offering upfront CRT to these patients, the decision based
purely on clinical staging, is risky. At our institution, the
initial staging of early low rectal cancer includes a high-
resolution pelvic MRI amongst other standard investiga-
tions. The results are discussed in our weekly multidisci-
plinary meeting where images are reviewed and manage-
ment options discussed. When the CRM is clear and the
tumour amenable to local resection, we tend to favour this
approach as first-line intervention and rediscuss the case
with the final histopathology report. It has the advantage of
providing accurate pathological staging on which to base
future management decisions. When further treatment is
recommended, we favour discussion with the patients re-
garding completion radical surgery versus CRT in an at-
tempt at organ preservation with close imaging and clinical
surveillance, knowing that the latter is not yet standard.
Although we have reported previously on the good onco-
logical outcomes of patients who decline surgery and un-
dergo adjuvant CRT [17], we prefer, if available, partici-
pation in research trials.
Patients with High-Risk Low Tumours
In rectal cancer, an incomplete resection is associated with a
higher risk of local recurrence and significantly worse out-
comes [18, 19]. The rate of R1 resection was traditionally
reported as high as 20–40% for low rectal tumours, partly
explained by the complexity of the surgical technique in such
a confined anatomical space [20–22]. TheMERCURY II trial,
investigating specifically low rectal tumours, validated an
MRI staging classification to document the relationship be-
tween the low rectal cancer surgical plane (mrLRP) and the
tumour [23••]. The overall rate of pCRM involvement in the
study was less than 10%, proving the value of mrLRP radio-
logical assessment. Furthermore, 4 factors were found onmul-
tivariate regression to be predictive of pCRM involvement: an
unsafe mrLRP, invasion from the tumour of the anterior quad-
rant of the rectum, a tumour height of less than 4 cm from the
anal verge and the presence of extramural vascular invasion
on MRI (mrEMVI). With these factors, the study group was
able to propose a predicted risk of pCRM involvement.
Tumours with none of the bad features mentioned above have
a risk of involved pCRM of 1%, whereas the risk is as high as
60% with tumours presenting all four factors. Based on this
data, nCRT is justified in patients with high-risk low tumours.
However, as emphasised in theMERCURY II study, restaging
investigations, including MRI and reassessment of the surgi-
cal plane is mandatory after nCRT. Patients who achieve a
cCR or nearCR could be offered organ preservation. In pa-
tients for whom surgery is inevitable, a ymrLRP MRI assess-
ment is crucial, as an unsafe plane carries a 25% risk of an
incomplete resection. These patients might therefore be can-
didates for intensified treatment, such as further consolidation
chemotherapy or surgery beyond TME with excision of the
compartments involved by the treated tumour.
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Patients with Advanced Cancer
Patients with locally advanced rectal cancer typically require
nCRT, for its proven benefit on locoregional control [2].
Those who reach a cCR following treatment could be candi-
dates for W&W. We have previously discussed the low rectal
tumours, but what about the proximal ones, those tumours for
which a low anterior resection with sphincter preservation is
feasible? There are some pros and cons of a NOM in these
cases. Firstly, avoiding surgery prevents, at least temporarily,
the patient from facing the possible consequences of a triple-
modality treatment on bowel, urinary and sexual function and
its impact on quality of life [24]. The low anterior resection
syndrome (LARS), which is characterised by symptoms such
as faecal incontinence, emptying difficulties, urgencies and
fragmented bowel movements, is a recognised entity and is
seen in as much as 90% of patients who undergo an anterior
resection [25–27]. Several studies have found that nCRT is a
significant factor of poorer functional outcomes after surgery.
Secondly, a radical procedure such as TME has its risks of
surgical complications, morbidities and mortality [6]. On the
other hand, one could argue that salvage surgery might poten-
tially be more challenging than an upfront procedure. This has
been described in anal cancer, where surgery is a salvage
strategy and carries a higher risk of complications [28, 29].
The late side effects of chemoradiation, including pelvic fibro-
sis, can complexify the surgical technique. Another argument
againstW&Win higher tumours is the unavailability of digital
rectal examination (DRE). Tumours over 6–7 cm from the
anal verge cannot be reached with the examining finger, and
DRE has been proven a helpful tool in tumour response as-
sessment and monitoring. At our institution, we favour imag-
ing modalities in our monitoring protocol, but agree that DRE
should not be completely discarded. The response assessment
will be further discussed below. Finally, and possibly the main
argument against W&W in the proximal tumours, is the lack
of data on long-term outcomes, as they have often been ex-
cluded from the studies.
In summary, when analysing data on W&W, the reader
should pay careful attention to the description of the popula-
tion included (stage of disease, methods of baseline and treat-
ment response assessments, quality of imaging). The limita-
tions of the data we have so far are related to the lack of
accurate staging or standardisation of selection policies for
CRT. Figure 1 summarises our current institutional policy
for rectal cancer management, including organ preservation
strategies.
What Is the Best Treatment—Duration
and Intensification of Treatment
Most series on W&W describe long-course chemoradia-
tion as the preferred neoadjuvant approach, with pelvic
radiotherapy of 45–54 Gy combined with either 5FU or
capecitabine being the most common regimen. However,
there are several studies looking at ways to optimise the
MRI staging 
T1/T2  
> 1 mm muscularis preserved 
mr cN0 
<4 cm diameter 
EMVI negative
Consider local 
excision 
No adverse 
pathology features 
Surveillance  Patient’s choice  
Presence of adverse 
pathology features 
Completion 
surgery  
(TME) 
Adjuvant CRT 
followed by 
3-6 monthly 
surveillance 
Low rectal cancer 
CRM involved 
CRT 
Enrol to TRIGGER 
Control arm
(cf protocol)
Interventional
arm  
Good response Poor response 
Consolidation 
chemotherapy 
Watch-and-Wait 
Good response 
Watch-and-Wait 
Poor response 
Surgery (TME) 
T3a/b 
N1c negative/Nany 
mid/upper rectum   
CRM clear 
EMVI negative
Surgery (TME) 
T3c 
CRM involved 
EMVI positive 
N1c positive
Fig. 1 Rectal cancer management
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therapy with the objective of increasing the pCR rate and
therefore potentially the rate of organ preservation.
Standard CRT
In the landmark study by the German Rectal Cancer Study
Group, in which patients were randomly assigned to preoper-
ative CRT versus postoperative CRT, the pCR rate in the pre-
operative group was 8% [30]. The treatment administered was
50.4 Gy of radiotherapy, combined with continuous infusion
of 5FU. Other studies, including a meta-analysis from the
Cochrane group, have reported rates of pCR of 11–16%
[31–33]. Organ preservation using this standard combination
of RT and 5FU or Capecitabine has shown good outcomes,
which will be discussed further below.
Short-Course Radiotherapy
There is very little evidence on W&W following short-course
radiotherapy. To our knowledge, the only data available
comes from a prospective study of organ preservation
(W&W or local excision) in elderly patients [34]. In a cohort
of 60 patients (age 70 years or older, cT1-4N0-3M0 rectal
adenocarcinoma), 30 were not candidates for chemotherapy
and were therefore offered short-course radiotherapy (SCRT)
with delayed assessment of the tumour response. The investi-
gators presented the results of this unplanned interim sub-
group analysis, in which they evaluated the feasibility of
SCRT with delayed evaluation of response in a W&W con-
text. The 30 patients in the SCRT group received 5 × 5 Gy
over 1 week, and 4 of them had a further 4 Gy boost in 1
fraction, 1 week after completing their radiotherapy. The
median interval between the last fraction and the response
assessment was 10.3 weeks. Six patients (20%) achieved a
cCR, and all entered a W&W surveillance program. With a
median follow-up of 21 months, 1 of those 6 patients ex-
perience tumour regrowth, and the management and out-
come of this specific patient is not described in the article.
The Stockholm III trial randomised patients between SCRT
followed by surgery within 1 week, SCRT followed by
surgery at 4–8 weeks and finally long-course radiotherapy
(LCRT) of 50 Gy followed by surgery within 4–8 weeks
[35]. Even though organ preservation was not part of this
trial, looking at the pCR rate can be informative when
discussing treatment strategies in W&W. No information
was given about the pCR rate with long-course RT.
Surgery at 1 week after SCRT led to a very low rate of
pCR of 1.7%, whereas delaying surgery to 4–8 weeks in-
creased it to 11.8%, which is still relatively low [36]. This
could indirectly indicate the superiority of long-course
chemoradiation in a W&W program.
Contact X-Ray Brachytherapy
In France (Lyon and Nice), Jean-Pierre Gérard and his team
have one of the largest experiences in contact x-ray brachy-
therapy (CXB) (Papillon technique). The results of their stud-
ies have provided strong evidence supporting the use of CXB
in selected cases, with high rates of organ preservation and
low rates of local recurrence [37, 38]. Sun Myint and col-
leagues also shared their experience with CXB [39]. They
reported on the rate of local regrowth in a context of organ
preservation, in 200 patients treated at their centre between
2003 and 2012. Their cohort comprised 17 patients with very
early tumours, less than 3 cm, who were offered CXB upfront
after declining surgery or being deemed non-surgical candi-
dates. The remaining patients were all patients with diverse
tumour stages, who received CRT (45Gy with concomitant
5FU or Capecitabine) or RT alone (dose not reported). These
patients had restaging investigations 6–8 weeks following
treatment, and those with a residual disease of less than
3 cm were offered further RT with CXB of 90 Gy in 3 frac-
tions. Again, all these patients either declined surgery or were
considered unfit for radical resection, hence the referral for
further treatment with CXB. A total of 144 patients achieved
cCR post CXB, and only 16 of them (11%) experienced local
regrowth. The authors argue in favour of CXB for tumour
boost, as it has shown one of the lowest reported rates of local
regrowth, but these results need to be interpreted cautiously.
All these tumours had already shown good regression, as only
those showing residual disease less than 3 cmwere eligible for
CXB. A selection bias might have been introduced, the cohort
including potentially only highly radiosensitive and biologi-
cally favourable tumours. Another study by Dhadda et al. has
also shown a low recurrence rate of 12%, with a similar cohort
of patients, but the same biases and critics apply [40]. The
Lyon R96-02 trial aimed to compare CXB with external beam
radiotherapy (EBRT), but the study was running at the end of
the 1990s [41]. The EBRT techniques were not as sophisticat-
ed as the current standard, the EBRTalone arm did not include
concomitant chemotherapy and the dose delivered (39 Gy in
13 fractions) is no longer recommended. The OPERA study
(NCT02505750) is a phase III international randomised trial
currently recruiting. Patients with cT2-T3a/b tumours, less
than 5 cm, are randomised between two techniques of boost
delivery following nCRT: EBRTof 9 Gy in 5 fractions, versus
CXB of 90 Gy in 3 fractions. Hopefully, it will provide an-
swers regarding methods of boost delivery and dose
escalation.
Addition of Consolidation Chemotherapy vs
Neoadjuvant Chemotherapy
Several groups have studied the intensification or addition of
chemotherapy in the neoadjuvant part of the treatment. The
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most frequently studied, and possibly the most promising, is
the addition of oxaliplatin. The CAO/ARO/AIO-04 trial in-
vestigated the addition of oxaliplatin, both pre- and postoper-
atively, to the standard regimen of nCRT [42••]. Patients with
cT3-4Nany or cTanyNpositive disease were randomised be-
tween two arms. The standard arm received nCRT (50.4 Gy
with 5FU) followed by surgery and 4 cycles of bolus 5FU.
The interventional arm received the same radiotherapy plus
infusional 5FU and oxaliplatin, followed by surgery and 8 cy-
cles of a combination of oxaliplatin, leucovorin and infusional
5FU. The treatment including oxaliplatin was well tolerated,
without significantly different side effects than the standard
arm. Furthermore, the oxaliplatin arm led to a pCR rate of
17% (104/596 patients), compared to 13% (81/615) in the
standard arm (p = 0.031). Many other groups have studied
the inclusion of oxaliplatin and, in addition to increased tox-
icities, none has resulted in a statistically significant improve-
ment of the pCR rate [43–46]. However, as mentioned by the
authors in the German study (CAO/ARO/AIO-04), the toxic-
ity of the chemotherapy regimen in these studies had a signif-
icant impact on the compliance, which could explain the pCR
rate.
More recently, the FOWARC trial randomised patients
with stage II-III rectal cancer between three arms: nCRT
(46–50.4 Gy with 5FU) followed by surgery and adjuvant
5FU, the same regimen with the addition of oxaliplatin
(mFOLFOX-6) and finally 4–6 cycles of mFOLFOX-6
followed by surgery and a further 6–8 cycles of mFOLFOX-
6 [47•]. The rate of pCR in the standard arm, mFOLFOX-6 +
radiotherapy arm and mFOLFOX-6 alone arm was, respec-
tively, 14, 27.5 and 6.6%. Understandably, the toxicities were
higher in the mFOLFOX-6 + radiotherapy arm, but surpris-
ingly the compliance was as good if not better than the stan-
dard arm group. A group from China performed a meta-
analysis on the addition of oxaliplatin to the standard 5FU-
based regimen of nCRT [48]. It included, amongst others, the
studies mentioned above, and found that the regimen includ-
ing oxaliplatin significantly increased the rate of pCR (RR =
1.24, 95% CI 1.02–1.51; p = 0.03). It also led to an improved
disease-free survival and lower rate of distant metastases.
In 2006, the Angelita & Joaquim Gama Institute, in São
Paulo, Brazil, changed their routine practice and started
offering an ‘extended’ nCRT regimen, which consists of
54 Gy in 30 fractions with concomitant chemotherapy
followed by a course of consolidation chemotherapy
(5FU and leucovorin for a total of 6 cycles: 3 cycles deliv-
ered every 21 days and 3 additional cycles delivered during
the resting period after radiotherapy completion). They re-
cently retrospectively compared the outcomes of patients
with cT2N0 disease in the standard regimen with the ex-
tended regimen and found that the extended regimen,
which was well tolerated, led to a significant increase in
the cCR rate (56.6 vs 85.7%) [12•]. Therefore, patients
who received the extended regimen were more likely to
be eligible to a W&W approach.
The Memorial Sloan Kettering Cancer Centre (MSKCC) is
currently running a phase II study in which patients are
randomised between induction chemotherapy followed by
nCRT, and nCRT followed by consolidation chemotherapy
(NCT02008656) [49]. Patients with a significant clinical re-
sponse to treatment are being management with a non-
operative strategy.
While some people investigate the intensification of treat-
ment, others are trying to customise it, for example by study-
ing the feasibility of omitting routine use of radiotherapy in
locally advanced rectal cancer. The MSKCC has done so in
2014 with a pilot study [50]. Thirty-two patients, with cT2-
T3Nany rectal adenocarcinoma received preoperative
infusional 5FU, leucovorin and oxaliplatin (FOLFOX) plus
bevacizumab. Patients who maintained a stable disease or
showed progression proceeded with neoadjuvant radiotherapy
prior to radical resection (TME), whereas patients who
responded to treatment went straight to surgery (TME). Four
patients needed radiotherapy: 2 patients preoperatively and 2
patients postoperatively for positive resection margins. The
pCR rate of patients who received chemotherapy alone was
25%. The GEMCAD 0801 trial investigated the safety and
efficacy of neoadjuvant chemotherapy alone (capecitabine,
oxaliplatin (CAPOX) and bevacizumab) in 46 patients with
T3 rectal adenocarcinoma with clear predicted resection mar-
gins onMRI, also in that case with a selective use of nCRT for
patients with progressive disease only [51, 52]. They achieved
similar results as the MSKCC pilot study, with a pCR rate of
20%. Although interesting, this strategy of offering nCRT
only to selected patients after an induction course of chemo-
therapy is not yet an approved treatment option outside of a
clinical trial. The small number of patients in both studies is a
limiting factor to draw any conclusion. The PROSPECT trial
(NCT01515787) is ongoing and should help further clarify the
role of neoadjuvant systemic chemotherapy alone. If organ
preservation is sought, radiotherapy should currently be in-
cluded in the treatment strategy.
High-Dose RT/Brachytherapy
We know that there is a strong correlation between dose of
radiotherapy and tumour response. In rectal cancer, the work
of Ann Appelt has helped to quantify it [53]. Her team
analysed the data on tumour regression from 222 patients with
rectal adenocarcinoma, treated with nCRT, and derived a
dose-response relationship. Tumour regression was defined
using the Mandard system. Total tumour dose was calculated
by adding the brachytherapy component of the treatment to
the external radiotherapy dose. ‘Complete response’ was de-
fined as TRG1, and ‘major response’was defined as TRG1-2.
They found a strong correlation between total tumour dose
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and tumour response, with 92.0 Gy being the dose resulting in
50% of response for TRG1, and 72.1 Gy for TRG1-2.
One way of escalating the RT dose is with endorectal
brachytherapy. One of its advantages over external beam RT
is that it can deliver high dose of RT to a localised area. The
exposure to surrounding healthy tissues is reduced, as the dose
decreases with distance from the source. Buckley and col-
leagues did a systematic review on high-dose-rate brachyther-
apy (HDRB) in rectal cancer [54]. They investigated the role
of HDRB alone, HDRB combined with CRT and HDRB in
the context of W&W. The weighted mean rate of pCR with
preoperative HDRB alone was 23.8% and with preoperative
HDRB combined with CRT, 22.2%. The main limitations of
this systematic review were the large variations in patient se-
lection, the lack of long-term outcomes and the significant
paucity of data on toxicities. Only one study used HDRB in
a context of W&W and reported good outcomes [55•]. The
treatment administered included CRT (60 Gy external beam
RTwith combined tegafur-uracil) followed by a 5-Gy HDRB
boost. Seventy-eight per cent of patients achieved cCR, and
25.9% of patients experienced local relapse but all were suc-
cessfully salvaged. Te Vuong and her team at McGill
University have accumulated years of experience in HDRB
and have reported good oncological outcomes in selected pa-
tients [56, 57]. The CORRECT trial (NCT02017704) is an
ongoing randomised study evaluating the effectiveness of
HDRB compared to standard nCRT in rectal cancer.
Understandably, it makes sense to aim for dose escalation,
knowing that it will likely provide higher tumour regression,
but in rectal cancer, caution is advised as the majority of pa-
tients will still go to surgery. It therefore might be inappropri-
ate to push the dose above a certain level. Patients could face
more complex surgeries, with a higher risk of complications
and could potentially have to deal with poorer functional out-
comes in the long term.
Timing of Assessment
There is an ongoing debate on the best interval between treat-
ment completion and response assessment. In the context of
W&W, the objective is finding the perfect balance between
greatest tumour regression, therefore increasing the patient’s
chance of being eligible for a W&Wapproach, while assuring
a safe and successful surgery, if surgery is inevitable. In the
studies reporting on W&W, another serious limitation is the
large variation on when these patients were identified and
how. Some series described reassessment at a fixed time point,
like 6, 8 or 10 weeks [55•, 58–62]. Others reported on re-
sponse reassessment undertaken during a rather large period
of time, for example 8 to 12 weeks, 4 to 10 weeks or simply
more than 8 weeks without further details [63–66]. In order to
clarify the optimal timing for restaging after neoadjuvant
treatment, we can take a look at what we know so far on
timing of surgery and its relation with the pCR rate.
Several retrospective studies have suggested a higher rate
of pCR when delaying surgery after nCRT [67–69]. Since
then, multiple prospective trials have been conducted to an-
swer the question on timing, but report conflicting results.
Garcia-Aguilar and colleagues published in 2011 the initial
results of a non-randomised phase II trial in which patients
with stage II-III rectal cancer receiving nCRT pursued either
TME at 6 weeks post treatment, or were given 2 cycles of
consolidation mFOLFOX-6 followed by TME a further 3–
5 weeks after completion of treatment [70]. The average time
interval between the last fraction of radiotherapy and surgery
was 6 weeks in the TME at 6 weeks group and 11 weeks in the
delayed group. The surgeries were equivalent in both groups,
without a significant increase rate of complications in either
group. The pCR rate, on the other hand, was higher in the
mFOLFOX-6 group compared to the standard group (25 vs
18%) although the difference was not statistically significant.
The same group of investigators updated their result fairly
recently, also adding a further 2 groups: one with 4 and one
with 6 cycles of consolidation mFOLFOX-6 [71]. All patients
underwent surgery at 3–5 weeks following the last cycle of
chemotherapy. Automatically, this led to each group with a
longer interval between nCRT and surgery: 8.5, 11.1, 15.4
and 19.3 weeks. The rate of pCR increased with the number
of cycles of chemotherapy, from 18% in the standard nCRT
group, to 25% in the 2 cycles of mFOLFOX-6 group, 30% in
the 4 cycles group and finally 38% in the 6 cycles group. It is
reasonable to believe that both the timing and the addition of
consolidation chemotherapy had an impact on the pCR rate,
but it is impossible to quantify the role of each.
The French Greccar-6 trial randomised 265 patients with
cT3-4Nany or cTanyNpositive rectal adenocarcinoma, who
completed nCRT, between surgery at 7 and 11 weeks post
completion of treatment [72••]. In that study, increasing the
interval between nCRT and surgery did not lead to a signifi-
cant difference of pCR rate (15 vs 17.4%, p = 0.5983).
Furthermore, increasing the interval to 11 weeks correlated
with a higher risk of morbidity and a more complex surgical
procedure. There were no significant statistical differences in
the rate of anastomotic leak, perineal healing problems and
mean hospital stay between the two groups. As opposed to
the Greccar-6 trial, other studies did not show any negative
impact of delaying surgery on the surgical outcomes and
complications/morbidity rates [73, 74].
A similar trial on timing of surgery was conducted in the
UK [75••]. In the 6 vs 12 study, 237 patients were randomised
between surgery at 6 versus 12 weeks post nCRT. More pa-
tients in the 12-week interval group showed tumour
downstaging (58 vs 43%, p = 0.019). The pCR rate was also
significantly higher in the 12-week arm (9 vs 20%, p < 0.05).
The results were presented in an oral abstract at the European
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Society of Medical Oncology (ESMO) annual meeting in
Copenhagen in October 2016, and the final report is awaited.
Sun et al. interrogated the US National Cancer Database
(NCDB) to answer the question on optimal timing [76]. The
database was questioned on patients treated between 2006 and
2012, who received nCRT followed by surgery for a stage II–
III rectal adenocarcinoma. The analysis included 11,760 pa-
tients. The investigators looked at the time between last frac-
tion of radiotherapy and date of surgery, with endpoints in-
cluding resection margin posit ivity, pathological
downstaging, unpredicted postoperative readmission within
30 days, 30 day mortality rate and overall survival. They also
aimed at finding an optimal time threshold for surgery (lowest
R1 resection rate while highest proportion of tumour
downstaging), which was found at 56 days (8 weeks) post
nCRT. The authors found out that tumour downstaging in-
creased during the waiting period, but passed 56 days, there
was no added benefit of delaying surgery. Similarly, the risk of
an R1 resection was stable until 56 days, but passed that time it
increased significantly. Interestingly, the investigators did not
find any threshold regarding readmission rate, 30-day mortal-
ity rate and overall survival. However, when looking at pa-
tients in the group who had surgery after the 56 days thresh-
old, adjusted and compared to the group < 56 days, patients in
the > 56 days group seemed to have a lower rate of
readmissions, same mortality at 30 days, but worse overall
survival (hazard ratio 1.2). Another group of investigators
has also interrogated the NCDB, over the same period
(2006–2011), and came with different results [77]. They di-
vided patients between 3 groups depending of the time inter-
val between nCRT and surgery: < 6 weeks, 6–8 weeks and >
8 weeks. 17,255 patients were included in the analysis. The >
8-week interval showed the best rate of pCR and
downstaging, and patients had lower rates of 30-day readmis-
sion. Surgery in the > 8 weeks group was not associated with
more complications or morbidity.
Petrelli and colleagues conducted a meta-analysis on
timing between nCRT and surgery, with the pCR rate as pri-
mary endpoint [78•]. Thirteen studies, of overall medium
quality, were included in the analysis. Investigators divided
results into 2 groups: surgery at < 8 weeks and surgery at >
8 weeks. The longer interval led to a higher rate of pCR (RR
1.42, p < 0.0001). There were no significant difference in the
overall survival, disease-free survival, rate of complete resec-
tion (R0), rate of sphincter preservation procedure and wound
and anastomotic leak events.
Despite several good quality studies and best efforts, the
optimal interval between nCRT and surgery, and similarly
between nCRT and response assessment in a W&W context,
has still not been established. In the absence of stronger evi-
dence towards a precise time point, clinicians who are consid-
ering W&W for their patients should organise response as-
sessment investigation between 6 to 12 weeks after
completion of treatment and restrain from the impulse of pro-
ceeding to surgery on those who do not show cCR at this
stage. Patients who have shown some degree of response
might actually benefit from longer waiting and perhaps con-
solidation chemotherapy in some of them.
Identification of Response
One of the major challenge in the NOM of rectal cancer is the
careful selection of patients suitable for this approach. The
objective is being able to identify patients who would have a
pCR if operated on, out of all those who achieve a cCR. For
the moment, the methods employed have several limitations,
and cCR does not correlate perfectly with pCR. In the original
publication from Habr-Gama and colleagues, 8.3% of the pa-
tients classified as incomplete responders had in fact a pCR on
examination of the final TME specimen [10]. Other groups
have reported even greater discordance. Creavin and col-
leagues showed that 15.9% of the patients in their cohort, after
having nCRT and being considered partial responders, had a
pCR [59]. In Maas and colleagues’ cohort of patients, out of
20 patients with a pCR, 15 of them had suspicion of residual
disease on imaging exams post nCRT [79].
Biopsy
At the time of response assessment, especially in the context
of W&W, many clinicians are concerned about residual dis-
ease and routinely proceed with biopsy. Even in the absence of
any residual mucosal abnormality, some people will proceed
with random biopsies of the treated scar area, with the hope of
being able to document a complete response. When a visible
abnormality is suspicious for residual disease, some people
would also proceed with biopsy, in that case to confirm the
presence of tumour and support the indication for surgery. The
São Paulo group did a retrospective comparative study to de-
termine the value of biopsies post nCRT [80]. They reported a
sensitivity of 50% and a poor negative predictive value of
11%, which might be explained by geographical miss. The
specificity and the positive predictive value were both
100%, meaning that when cancer cells were found on the
biopsy, it resulted in confirmed residual cancer in the resected
specimen in all cases. These numbers are derived from only
three biopsies truly negative and therefore should be taken
cautiously. Nevertheless, some people will say that a positive
biopsy is enough evidence on its own to proceed with surgery.
We disagree, and question the justification of surgery on the
basis of a few cells discovered in the sample, without any way
of proving their viability. The aspect of timing is also crucial
here. A biopsy taken at 6 weeks might be completely different
than one taken at 12 weeks. We know that tumour regression
continues beyond 8 weeks, but what if it is still the case after
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12 weeks? That is the reason why we strongly favour the
concept of regrowth. A biopsy reflects the situation at a pre-
cise time point. In our opinion, monitoring for regrowth, using
imaging modalities and clinical examinations, for example, is
a more reliable measure as it takes into account the notion of
time. If there is evidence of regrowth, than the residual cells
have proven their viability and their ability to proliferate. That
is when an intervention, in most cases salvage surgery, should
be considered, but a randomised trial is needed if such an
approach is to be adopted to ensure that patients are not dis-
advantaged during this wait period through the development
of metastatic disease.
Transanal Endoscopic Microsurgery (TEM)
In order to maximise the chances of organ preservation,
some investigators have described a new entity, the ‘near
complete response (nearCR)’. It usually refers to tumours
that show a very good response to treatment, but do not
fulfil all criteria for a cCR. When a patient presents a
nearCR, some people would favour TEM when technically
feasible and have described good rates of organ preserva-
tion with this approach [59, 62]. Proceeding with TEM
avoids the geographical miss that is possible with random
biopsies, but timing is still an issue. In a study by Martens
et al., patients who achieved a nearCR after nCRT were
offered the choice between reassessment in a further
3 months, versus TEM [60]. Thirty-nine patients presented
with a nearCR. Fifteen of them opted for TEM, amongst
which 9 (60%) had confirmed pCR. All the remaining 24
patients who opted for further reassessment eventually
achieved a cCR and entered the W&W program. The
CARTS study was a prospective multicentre trial in which
patients with early-stage cancer, eligible for TEM,
underwent the procedure after nCRT [81]. The aim of the
study was to accurately determine the number of patients
with minimal residual disease (ypT0-1). Out of 51 patients
who completed nCRT (50–50.4 Gy in 25–28 fractions with
concomitant capecitabine), 47 experienced significant tu-
mour regression (ycT0-2) and underwent TEM. There were
21 patients showing pCR (ypT0N0), 9 patients with
ypT1N0 and 17 patients with ≥ypT2 and/or N+ disease.
Twenty-eight per cent of patients who had TEM experi-
enced postoperative complication. On top of the inevitable
risk of overtreatment, TEM after CRT may result in poorer
functional outcomes [14•, 24, 82•]. TEM should only be
considered in a very selective group of patients following
nCRT. The 21 patients with pCR in the CARTS study were
obviously overtreated, and we believe that some of the
patients with residual disease would probably have pCR
as well, if allowed more time to achieve it. In the study,
TEM was undertaken 8–10 weeks following the last frac-
tion of RT.
DRE/endoscopy
The definition of cCR varies between published series on
W&W, but the most commonly used is the one proposed by
Habr-Gama and colleagues [83]. On endoscopic and clinical
evaluation, a whitening of the rectal mucosa can be observed,
with or without associated telangiectasia (Fig. 2). The rectal
wall can also show loss of pliability. Possible signs of incom-
plete response are, on endoscopy, the observation of any re-
sidual ulcer (deep or superficial, with or without a necrotic
centre), significant stenosis and on digital examination the
palpation of any residual nodule.
Most, if not all, series on W&W have included DRE and
endoscopy as part of the reassessment protocol. We agree that
those are helpful tools; however, they are not sufficient on
their own. More prominent fibrotic changes could be easily
interpreted as residual disease at the site of the primary tu-
mour. Therefore, imaging might be a more robust and less
subjective method of assessing response.
PET-CT
Positron emission tomography and CT (PET-CT) is an imag-
ing modality actively studied in the context of treatment re-
sponse assessment. Given the fact that a metabolic complete
response does not indicate pCR in all cases, a number of
factors are being looked at to increase the value of PET-CT
in a W&W context: a reduction in the maximal standardised
uptake value (SUV), the total lesion glycolysis (TLG) and its
percentage change and the metabolic tumour volume (MV),
for example. In a series by Perez et al., the accuracy of PET-
Fig. 2 Maintained complete response of a rectal tumour, 4 years
following chemoradiation. A typical appearance scar is visible, with no
evidence of tumour recurrence
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CT to predict cCR was 91% and increased to 96% when
combined with clinical assessment [84].
MRI
Magnetic resonance imaging (MRI) is a powerful tool to as-
sess tumour response. There has been great interest in two
different sequences of MRI: the standard MRI (mostly T2-
weigthed sequence to assess changes within the treated tu-
mour) and the diffusion-weighted MRI (DW-MRI). In any
case, MRI should be of high quality to enable visualisation
of fine details of the tumour spread as well as assessment of
tumour response. For the last decade an MR-modified
Mandard grading system (mrTRG) has been used to identify
fibrosis/residual tumour signal and categorise patients in
groups depending on the qualitative changes within the treated
tumour [85]. mrTRG has also been proven to correlate with
ypT and be a predictor of outcomes in rectal cancer patients
[86]. According to mrTRG grading system patients are
categorised in 5 groups:
– TRG1—thin fibrosis, low-density signal on T2-weighted
images with no evidence of intermediate signal intensity
at the site of the treated disease
– TRG2—dense fibrosis with no macroscopic evidence of
intermediate T2 signal intensity (Fig. 3)
– TRG3—predominating low signal fibrosis with macro-
scopic scattered or local intermediate signal intensity
– TRG4 and TRG5—predominating intermediate T2-
weighted signal with minimal or no fibrosis present
(Fig. 4)
This imaging method of assessment response has been test-
ed in a number of international prospective trials and con-
firmed to be an independent factor of prognosis and also
shows to be a reproducible imaging tool [87]. Furthermore,
a recent analysis showed that mrTRG is 10 times more likely
to identify patients with complete pathological response when
compared with clinical assessment, particularly residual mu-
cosal abnormality [88]. A number of investigators have been
particularly interested in the diffusion-weighted (DW) imag-
ing proposing that this method could improve specificity of
patients’ selection with complete response. Supporters of the
DW imaging approach are suggesting that residual high signal
intensity at the site of the treated tumour on high b-values
images is indicative of areas of residual tumour and these
patients should not be offered deferral of surgery approach.
However, results of the Maastricht group work showed that
clinical assessment with additional DWI missed 15% of pa-
tients with complete pathological response [89]. Currently,
there is no evidence to indicate that apparent diffusion coeffi-
cient (ADC) measurements improve accuracy in detecting
Fig. 3 Low rectal tumour before
treatment with full invasion of the
muscularis at 4–8 o’clock
position. The tumour borders the
intersphincteric plane, therefore
the CRM is involved at the level
of the distal levators (a). Post
CRTMRI demonstrates an area of
low signal fibrosis at the site of
the treated tumour, and no
evidence of macroscopic residual
intermediate signal suggestive of
tumour—mrTRG2 (b)
Fig. 4 Low rectal tumour before
treatment, infiltrating the rectal
wall at 5–10 o’clock position with
evidence of spread beyond the
muscularis and spread into the
intersphincteric plane, with
invasion of the right levator (a).
On post CRT MRI, the treated
tumour demonstrates intermediate
signal predominantly suggestive
ofmacroscopic residual disease—
mrTRG4 (b)
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patients with a good response to treatment or that it provides
any added value when mrTRG is utilised and studies have not
yet been able to validate cut-off values or definitions for good
versus poor response using DWI or ADC values that can be
prospectively tested against survival outcomes [90–92].
Results of the Deferral of Surgery trial suggest that use of
DWI protocols and PET/CTwould have excluded over 30 and
60% of patients respectively with no regrowth for at least
1 year. Therefore, mrTRG appears to be the most sensitive
method of finding patients with pCR not compromising the
regrowth rates when compared with clinical assessment and
DWI, PET/CT findings. This data was presented in an oral
abstract at the European Society of Gastrointestinal and
Abdominal Radiology (ESGAR) annual meeting in Prague
in 2016, and the final report is awaited.
Other Imaging Modalities
The modalities discussed above, namely clinical assessment,
MRI and PET-CT, are the most frequent tools used in a W&W
management. Endoscopic ultrasound, although proven valu-
able for the initial staging of rectal cancer, is unfortunately not
the most helpful in tumour reassessment post treatment. The
images are often distorted and even an experienced eye may
struggle in differentiating residual tumour from chemoradia-
tion change [93•]. Similarly, the standard CTscan, due to poor
soft tissue contrast, has shown low accuracy of less than 50%
to assess and predict pCR [93•].
The published series on W&W have all used different mo-
dalities to assess response post nCRT. The MSKCC has cre-
ated a three-tiered evaluation plan (The Regression Schema)
that includes endoscopy, DRE, T2 weighted MRI and DW-
MRI. The findings defined for each modality are used to di-
vide patients between complete responders, near complete
responders and incomplete responders. This assessment pro-
tocol is currently being tested and validated in the MSKCC
phase II multi-institutional trial mentioned earlier [49]. At our
institution, we favour mrTRG and are validating this biomark-
er in the TRIGGER feasibility trial [94••]. In the interventional
arm of the trial, the patient is classified as either ‘good’ or
‘poor’ responder, based on mrTRG only. We do not take into
account DRE and endoscopy findings at this point. Good re-
sponders undertake 12 weeks of consolidation chemotherapy
and enter a surveillance program (deferral of surgery arm).
Poor responders receive 12 weeks of consolidation chemo-
therapy before being reassessed with a further MRI. Patients
who then fulfil the criteria for good responders enter the same
surveillance program. Patients still deemed poor responders
are referred for radical surgery. Endoscopy and DRE are used
in the surveillance protocol, and their findings are taken into
account when there is suspicion of regrowth. The trial flow-
chart is summarized in Fig. 5.
What Is the Evidence that We Can Predict
Response/Risk of Regrowth from Baseline
Characteristics?
Several investigators have tried to determine and better under-
stand factors that may predict response to CRT. This is an
attractive field of research, as it has the potential to help clini-
cians select the appropriate candidates for organ preservation.
A group of investigators has developed a nomogram to predict
pCR post nCRT in locally advanced rectal cancer [95]. It
includes as predicting factors pre- and post-treatment CEA
level, distance from anal verge, circumferential extent of tu-
mour and tumour size, and the authors report a 75–80% accu-
racy of the model to predict pCR. Other researchers have
developed similar nomograms, using different factors [96,
97]. This is interesting and could indeed give us an idea of
the likelihood of achieving pCR, but these nomograms will
always remain imperfect. There are still so many confounders
that have the potential to influence the tumour response and
possibly regrowth for those patients managed with W&W.
Tumour-Related Factors
Rectal cancers represent a group of diverse tumours, with
inherent characteristics that can potentially influence the out-
come of the treatment. Histology is one of them. The vast
majority of tumours are adenocarcinoma, but subtypes include
mucinous cancers which come with poorer outcomes and rel-
ative resistance to CRT [98]. Also, tumours that macroscopi-
cally look similar can express a wide range of different muta-
tions. Furthermore, there is intratumoral heterogeneity, which
illustrates the danger of supporting a management strategy and
predict pCR on a biopsy sample only. The São Paulo group
studied this concept, and by looking at somatic mutations in
different fragments of a same tumour, found that the majority
of the mutations (60%) were present in only one fragment,
with only 27% of mutations being expressed in all fragments
[99]. Similarly, two rectal cancer patients with the same over-
all burden of disease can express different carcinoembryonic
antigen (CEA) levels. Several studies have found the CEA
level, either prior to any treatment or after nCRT before radical
surgery, to be a strong factor of tumour regression and pCR
[100–102]. The location of the tumour within the rectum, its
size, its circumferential extent, have all been recognised as
possible predictive factors of response [103, 104].
Patient-Related Factors
There are many characteristics of the host that could poten-
tially influence the outcome of the treatment. Examples in-
clude the immune system, the presence of chronic disorders
such as inflammatory bowel disease or diabetes and active
cigarette smoking. Medication might be an important
Curr Colorectal Cancer Rep (2018) 14:37–55 47
confounder, for example immunosuppressor agents like cy-
closporin, tacrolimus or even simple corticosteroids. There is
not much data on medication and response to treatment, but
researchers have found that the use of statins increases tumour
regression with CRT [105–107]. There are at least two phase
II trials currently running that investigate the value of adding a
statin to nCRT in rectal cancer (NCT02161822 and
NCT02569645). Similar to the CEA level, the link between
the neutrophil-lymphocyte ratio (NLR) or other inflammatory
markers and tumour regression is being studied and is prom-
ising [108–110].
External Factors
The treatment administered, including the modality, the dose,
the delays or interruptions, obviously has an impact on the
outcomes. Timing, discussed in details earlier, has also a
major influence on the response to treatment. Other possible
confounders, on which there is paucity of data, include other
interventions, like trauma from multiple biopsies, for exam-
ple. Could it have an impact on the risk of regrowth?
Monitoring of Patients
There are differences between monitoring residual disease and
monitoring a cCR. As discussed above, at our institution, we
favour the surveillance for absence of regrowth, irrespective
of residual tumour. We have said earlier that, from our point of
view, biopsies are unnecessary and we also believe they might
actually be harmful. Unless we find a way of proving viability
of tumour cells, waiting and monitoring for regrowth is pref-
erable. The TRIGGER trial, discussed earlier, allows patients
who have shown a good response, but in whom the possibility
Fig. 5 TRIGGER trial flowchart
(summary). Further details are
available in the protocol,
including chemoradiotherapy
regimen, chemotherapy agents
and number of cycles
48 Curr Colorectal Cancer Rep (2018) 14:37–55
of residual tumour is not excluded, to be further reassessed
and monitored for regrowth [94••]. Some people are sceptical
of this approach and argue that there is a risk of distant metas-
tasis with residual tumour. However, the data on W&W has
shown good outcomes, including rate of distant metastasis
(oncological outcomes are discussed further below). We agree
that there is a lack of long-term data on W&W, including
especially the risk of late distant recurrences, and that is why
a randomised controlled trial such as TRIGGER provides a
safer environment to investigate this treatment strategy.
The surveillance protocol in a NOM approach differs in the
studies published so far, but like the identification of response
process, it usually includes a combination of clinical exami-
nation, monitoring of CEA level, flexi-sigmoidoscopy and/or
complete colonoscopy and imaging exams. No clear recom-
mendation as to the best surveillance program has been de-
fined, but several series have reported that the vast majority of
regrowths occur in the first 2 years after completion of treat-
ment. Therefore, most clinicians agree that until better under-
standing of the disease and more accurate predictors of relapse
are known, the monitoring protocol should be intensive, at
least for the first 2 years. Most groups of investigators have
opted for clinical visits and exams every 1–3 months for the
first 2 years. Consequently, patients who are being offered
W&W should be fully aware of the implications of such an
intensive program and should be given a summary of the
surveillance schedule. Patients on whom the clinician has a
doubt regarding compliance might not be good candidates for
a W&W strategy, and clinicians should raise their concerns
with their patients when that is the case.
The Deferral of Surgery trial (NCT01047969), a prospec-
tive study of patients managed with W&W in a controlled
surveillance program, has been running at the Royal
Marsden Hospital, in the UK, and recently completed recruit-
ment. Its follow-up schedule is summarised in Table 1. Of
note, biopsies should not be done routinely, but only if re-
growth is suspected and should be taken only after MRI and
PET-CT are performed to reduce the rate of false-positive
finding on imaging. These proposed guidelines could be use-
ful for clinicians who wish to put in place a W&W program at
their own centre.
Quality of Life
Since the NOM approach in rectal cancer is fairly recent, little
is known regarding the functional outcomes and quality of life
of patients being managed with this strategy. Some authors
have attempted comparing it with anal cancer, in which the
first-line treatment is definitive chemoradiation, but such a
Table 1 Follow-up schedule in
the Deferral of Surgery trial Timeline from end of CRT DRE CEA Scans Endoscopy
4–8 weeks ✓ ✓ MRI
8–12 weeks ✓ ✓ MRI, FDG-PET
16 weeks ✓ ✓ MRI, FDG-PET
6 months ✓ ✓ MRI Flexi-sigmoidoscopy
9 months ✓ ✓ MRI Flexi-sigmoidoscopy
12 months (1 year) ✓ ✓ CT, MRI, FDG-PET Colonoscopy
15 months ✓ ✓
18 months ✓ ✓ MRI Flexi-sigmoidoscopy
21 months ✓ ✓
24 months (2 years) ✓ ✓ CT, MRI Flexi-sigmoidoscopy
30 months ✓ ✓
36 months (3 years) ✓ ✓ CT, MRI Flexi-sigmoidoscopy
42 months ✓ ✓
48 months (4 years) ✓ ✓ MRI Flexi-sigmoidoscopy
54 months ✓ ✓
60 months (5 years) ✓ ✓ MRI Colonoscopy
72 months (6 years) ✓ ✓ MRI Flexi-sigmoidoscopy
84 months (7 years) ✓ ✓ MRI Flexi-sigmoidoscopy
96 months (8 years) ✓ ✓
108 months (9 years) ✓ ✓
120 months (10 years) ✓ ✓ Colonoscopy
CRT chemoradiation treatment, DRE digital rectal examination, CEA carcinoembryonic antigen
Curr Colorectal Cancer Rep (2018) 14:37–55 49
comparison is inadequate. This is mostly due to the different
chemotherapy regimen, radiation fields, doses and dose
distribution.
Only few publications on W&W have reported quality of
life (QoL) outcomes. Appelt and colleagues did a prospective
observational study on patients with cT2-3N0-1 resectable
rectal adenocarcinoma between 0 and 6 cm from the anal
verge, treated with nCRT [55•]. The radiation dose was higher
than standard, with the gross tumour receiving up to 60 Gy by
external beam radiotherapy, followed by a 5-Gy boost by
endorectal brachytherapy (equivalent total dose on tumour
66 Gy). The concomitant chemotherapy was oral tegafur-ura-
cil. Patients with evidence of cCR following nCRT entered an
active surveillance protocol. Investigators assessed toxicities,
function and QoL using The European Organisation for
Research and Treatment of Cancer (EORTC) colorectal
cancer-specific QoL module (QLQ-CR29) and the Jorge-
Wexner scale for faecal incontinence. The EORTC question-
naire was completed prior to start nCRT, at the end of treat-
ment, at 6 months post treatment, 12 months post treatment
and on a yearly basis thereafter. Faecal incontinence was re-
corded at every visit. A total of 40 patients formed the obser-
vation group (W&W). Eighteen of 25 patients (72%) reported
no faecal incontinence at 1 year and 11 of 16 (69%) at 2 years.
The EORTC scores remained quite similar during the study
period. The median score at baseline (38 patients) was 9.7, at
12 months 10.1 and at 24 months 13.8. The most frequent late
toxicity reported was rectal bleeding (78% of patients), of
mild severity in the majority of patients.
As mentioned in a previous section, Martens and col-
leagues prospectively studied a cohort of patients who re-
ceived standard nCRT, achieved a cCR andwere consequently
offered an organ preservation strategy [60]. Patients with a
cCR followed an active surveillance schedule, whereas pa-
tients who had a nearCR had two choices: to proceed with
transanal endoscopic microsurgery (TEM) or to continue with
surveillance in a further 3 months, at which point decision
would be made between W&W and TME. Faecal inconti-
nence was assessed using the Vaizey score. Patients with a
minimum of 3 years of follow-up were offered to complete
the questionnaire. A total of 100 patients entered the program.
There were 61 patients with an initial cCR who followed the
W&W surveillance protocol, 24 patients with a nearCR who
ended in the W&W program after a second assessment con-
firmed cCR and finally 15 patients with a nearCR who
underwent TEM. Forty-five patients with no evidence of re-
growth and at least 3 years of follow-up were approached to
complete the Vaizey questionnaire, which measures faecal in-
continence. Twenty-nine patients agreed to complete it (22
W&W and 7 TEM). Patients in the W&W group reported a
better continence, with a mean score of 3.4, compared to the
TEM group with a 9.7 mean score (p = 0.003). One patient in
the W&W group, and 3 in the TEM group, reported major
incontinence, defined as a score above or equal to 12. The
same group of investigators published earlier in 2011 the ini-
tial results of their pilot study, in which they measured the
functional outcome of 21 patients in a W&W program [79].
They used the MSKCC bowel function questionnaire and
assessed faecal incontinence with the Wexner incontinence
score. Results were compared with those of a cohort of pa-
tients having pCR following nCRT and TME. Patients in the
W&W group showed better bowel function score and lower
incontinence score compared to the pCR group: they seemed
to be less affected by food intake, were less likely to use pads,
had better control over flatus and reported less changes in their
bowel habits.
Habr-Gama and colleagues also evaluated the anorectal
function of their cohort of patients managed with W&W
(cCR patients) or TEM (nearCR patients) [82•]. The function-
al outcome was assessed at least 8 weeks after treatment in the
W&W group and at least 6 months after the procedure in the
TEM group. They used the Cleveland Clinic Incontinence
Index (CCII), performed anorectal manometry with the
ALACER manometer (Multiplex II) and finally evaluated
quality of life with the Fecal Incontinence QoL Index Scale
(FIQL). The results of all assessments were better in the
W&W group compared to the TEM group. For the W&W
group, results in each category of the FIQL were (4 being an
optimal score): lifestyle 3.5, coping/behaviour 3.4,
depression/self-perception 3.4 and embarrassment 3.5, where-
as in the TEM group results were, respectively, 3.0, 2.7, 3.1
and 3.1. The CCII score was 2.3 in the W&W group, com-
pared to 6.5 in the TEM group.
In the Deferral of Surgery trial, bowel function and QoL
data have been prospectively collected, using the
LENT/SOMA system for acute and late toxicities, the
EORTC QLQ-C30 Questionnaire, a Modified Inflammatory
Bowel Disease Questionnaire and the Vaizey Incontinence
Questionnaire. It will provide precious information on func-
tional outcomes and QoL.
Outcomes and Management
of Regrowth/Relapse
Dossa and colleagues did a systematic review and meta-
analysis on the safety and outcomes of a W&W approach in
patients achieving cCR [111••]. They analysed the combined
evidence on rate of local regrowth and salvage therapy and
compared the rates of relapse and survival outcomes between
patients managed with NOM and patients managed with sur-
gery. They defined local regrowth as evidence of intraluminal
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tumour detected clinically, endoscopically or radiologically.
Nodal disease was considered as non-regrowth recurrence,
which also included any non-luminal intrapelvic disease or
distant metastatic disease. The final analysis included 23 stud-
ies, with a total of 867 patients. The pooled rate of local re-
growth was 15.7% (95% CI 11.8–20.1), and following a re-
growth, the pooled rate of salvage therapy was 95.4% (95%
CI 89.6–99.3). For those patients undergoing salvage surgery,
the rate of sphincter preservation was 49.8% (95% CI 33.0–
66.6). Compared to patients managed with surgery, patients
being followed in a W&W protocol did not have any signifi-
cant difference in non-regrowth recurrence, cancer-specific
mortality and overall survival. Based on their results, the au-
thors were able to estimate that out of 1000 patients managed
byW&W, only 2 patients would not be candidates for salvage
therapy given the extent of their locoregional disease, and one
patient would not be a candidate because of the presence of
metastatic disease.
Kong et al. also undertook a systematic review on the out-
comes of the W&Wapproach [112••]. They measured the rate
of local regrowth, salvage surgery, disease-free and overall
survival. For their analysis, they considered tumour regrowth
and local (rectal) recurrence as the same event for patients
managed with W&W and named it tumour regrowth. They
defined local recurrence as any evidence of relapse after sur-
gery, either immediate surgery or salvage surgery. Nine stud-
ies met the inclusion criteria and were included in the final
review, with a total of 370 patients in the W&W group. The
rate of tumour regrowth was 28.4%, with a rate of salvage
surgery of 83.8%. The rate of distant recurrence without tu-
mour regrowth was 1.9%. The reasons for not undertaking
salvage surgery was equal (about a third each) between: pres-
ence of distant metastases, patients unfit for surgery and pa-
tients declining surgery. The rate of distant recurrence was
similar between patients in the W&W group and patients hav-
ing immediate surgery. Disease-free survival and overall sur-
vival differed between studies, but it ranged from 97% at
2 years to 91% at 5 years for OS and 88% at 2 years to 68%
at 5 years for DFS, without any significant difference when
compared to patients having a pCR after immediate surgery.
In 2014, a group of expert within the Champalimaud
Foundation and EURECCA (European Registration of
Cancer Care) established the International Watch and Wait
Database (http://www.iwwd.org). The objective of this
project is to gather the evidence on W&W strategies, by
combining the existing retrospective data and the data
prospectively collected. In August 2016, the database
included 775 patients, and the first report was presented by
Dr van der Valk at the annual ASCO GI meeting in January
2017 [113•]. With a median follow-up time of 2.6 years, the
rate of local regrowth was 25%, and 84% of these regrowths
occurred in the first 2 years after treatment. Ninety-six per cent
(96%) of the regrowths were intraluminal, and 4% were
locoregional nodal recurrence. Seven per cent (7%) of patients
developed distant metastatic disease. The OS at 3 years was
91%.
Conclusion
The future is promising with regard to organ preservation in
rectal cancer, and interest is growing fast. Despite some major
advances in the last few years, there are still many challenges
and aspects of the strategy that need refinement. The selection
of patients, the identification of accurate predictors of re-
sponse and the increase in response rates by intensifying treat-
ment yet offering an acceptable toxicity profile are all exam-
ples of exciting areas of development. With the evidence we
have so far, we could reasonably predict that the treatment of
rectal cancer is likely to be tailored and risk-adapted to each
specific patient. For example, patients who show some re-
sponse to nCRT could be monitored and be allowed longer
delays in order to let them achieve the best possible response.
Some tumours might take more than 12 weeks to achieve
cCR, and with a careful surveillance program, this approach
should not compromise in any way the patient’s ultimate out-
come. On the other hand, patients who do not respond to
treatment are unlikely to benefit from longer waiting period
and should proceed with surgery at a time point that allows a
safe and successful procedure. Alternatively, theymight be the
ideal candidates for further chemotherapy.
Currently, there is no level I evidence to support a W&W
approach in patients achieving cCR after nCRT for rectal ad-
enocarcinoma. The aim of the International Watch and Wait
Database is to provide the strongest available evidence on the
W&Wmanagement strategy. However, this database seems to
combine a heterogeneous group of patients, stages, assess-
ments and monitoring protocols that may lead to inaccuracy
of results. Moreover, one of the main concerns with W&W is
the lack of long-term data, especially on patients who experi-
ence regrowth, to confirm the safety of this approach. A
randomised controlled study like the TRIGGER trial will pro-
vide more reliable answers.
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